Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020 - Aziyo

News & Press.

Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020

Nov 5, 2020 | News & Press

SILVER SPRING, Md. – November 5, 2020 – Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its third quarter earnings results after market close on Thursday, November 19, 2020. Management will host a conference call to review the company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the Aziyo Biologics, Inc. website at www.aziyo.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (833) 665-0667 (US/Canada) or (914) 987-7319 (International) and use the conference ID number 7952289 approximately ten minutes prior to the start time.

About Aziyo Biologics

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.

Media:
Courtney Guyer
Aziyo Biologics, Inc.
PR@aziyo.com

Investors:
Leigh Salvo or Caroline Paul
Gilmartin Group
investors@aziyo.com

Want to Stay up to Date on the Latest News?

Click below to join our mailing list.
External links are provided for informational purposes only.
 
Aziyo bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.
CANCEL     CONTINUE